Natick, Mass.-based early-stage cancer detection startup Mercy BioAnalytics closed its oversubscribed Series A funding round at $41M.
Mercy is pioneering an extracellular vesicle-based liquid biopsy
procedure for early cancer detection. The firm intends to use the
proceeds to accelerate the development and commercialization of Mercy
Halo test for lung cancer screening.
- Part of the fresh funds will be earmarked to develop detection tests for other types of cancer, starting with ovarian cancer.
- Novalis
LifeSciences led the funding round with participation from Sozo
Ventures, iSelect fund, American Cancer Society, BrightEdge, Broadway
Angels, and others.
- Labcorp and Bruker joined as strategic investors in the round.
- Prior to the Series A round, the firm raised over $27M in venture funding.
